REGENERATIVE MEDICINE COMMITTEE APPROVALS: LEGAL FRAMEWORK, REGULATORY REQUIREMENTS AND JUDICIAL ANALYSIS

1. INTRODUCTION

Regenerative medicine committee approvals are regulatory and ethical authorisations required for research, clinical trials, and therapeutic applications involving stem cells, cellular therapies, tissue engineering, gene-based interventions, and other regenerative technologies.

These approvals ensure that innovative medical treatments satisfy scientific, ethical, clinical, and public safety requirements before being administered to human participants. In India, the regulatory framework involves the Central Drugs Standard Control Organisation (CDSCO), Institutional Ethics Committees (IECs), the Department of Health Research (DHR), and the Indian Council of Medical Research (ICMR).

The principal objective is to prevent unproven treatments, protect research participants, ensure informed consent, and establish accountability among researchers, manufacturers, hospitals, and regulatory authorities.

2. IMPORTANT REGULATORY COMMITTEES

A. INSTITUTIONAL ETHICS COMMITTEE (IEC)

The IEC evaluates research protocols involving human participants. Its responsibilities include examining informed consent, participant selection, potential risks, confidentiality, and ethical acceptability.

B. INSTITUTIONAL COMMITTEE FOR STEM CELL RESEARCH (IC-SCR)

Under the National Guidelines for Stem Cell Research, 2017, this committee historically provided specialised scientific and ethical oversight of stem cell research. However, its regulatory position changed following the dissolution of NAC-SCRT in March 2024.

C. NATIONAL APEX COMMITTEE FOR STEM CELL RESEARCH AND THERAPY (NAC-SCRT)

Historically, NAC-SCRT provided national-level oversight of stem cell research, particularly restricted research activities. It was dissolved through the DHR order dated 3 March 2024. Its former functions must therefore not be treated as the current approval procedure.

D. CENTRAL DRUGS STANDARD CONTROL ORGANISATION (CDSCO)

CDSCO regulates applicable cell-based products, stem-cell-derived products, clinical trials, and manufacturing permissions under the Drugs and Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019.

3. LEGAL FRAMEWORK GOVERNING APPROVALS IN INDIA

Drugs and Cosmetics Act, 1940: Provides statutory regulation of substances intended for diagnosis, treatment, mitigation, or prevention of diseases.

New Drugs and Clinical Trials Rules, 2019: Establish clinical trial approval, ethics committee registration, participant protection, and regulatory requirements for applicable stem-cell-derived products.

National Guidelines for Stem Cell Research, 2017: Establish scientific, ethical, and safety standards for stem cell research.

ICMR National Ethical Guidelines, 2017: Provide ethical requirements for biomedical research involving human participants.

National Medical Commission Act, 2019: Provides the framework for medical professional conduct and ethical accountability.

Constitution of India, Article 21: Protects life, personal liberty, and patient autonomy.

4. APPROVAL PROCEDURE AND COMMITTEE RESPONSIBILITIES

A. SCIENTIFIC AND ETHICAL REVIEW

Research proposals must undergo appropriate scientific assessment and institutional ethical review before human participation begins.

B. PRODUCT CLASSIFICATION

The degree of cellular manipulation determines the applicable regulatory pathway. Substantially manipulated stem-cell-derived products intended for therapeutic use fall within the new-drug framework under the NDCT Rules, 2019.

C. CDSCO AUTHORISATION

Clinical trials involving regulated stem-cell-derived products require prior permission from the Central Licensing Authority, following the applicable Ethics Committee approval.

D. SPECIALIST ETHICAL REVIEW

Following the dissolution of NAC-SCRT, the DHR order requires ethics committees reviewing stem cell research involving human participants, biological materials, or data to include at least two stem cell experts, with at least one external expert.

E. CONTINUOUS MONITORING

Approved research must maintain appropriate safety monitoring, adverse-event reporting, clinical documentation, and participant protection.

5. IMPORTANT JUDICIAL DECISIONS

1. Yash Charitable Trust v. Union of India (2026 INSC 96)

The Supreme Court examined the legality of stem cell therapy for autism spectrum disorder. It held that such treatment cannot be offered as routine clinical care without credible scientific evidence and must be undertaken within an approved and monitored research or clinical-trial framework. This is direct authority concerning regenerative medicine regulation.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court established essential requirements of valid informed consent, including adequate disclosure of the treatment's nature, benefits, risks, and alternatives. This is directly relevant to regenerative medicine clinical trials.

3. Jacob Mathew v. State of Punjab (2005)

The Supreme Court explained the standards governing criminal medical negligence. Medical professionals conducting regenerative procedures must exercise appropriate professional care and competence.

4. Indian Medical Association v. V.P. Shantha (1995)

The Court recognised the applicability of consumer-protection law to medical services, subject to its stated principles. This provides relevant authority for claims arising from deficient regenerative medicine services.

5. Chimanlal Jagjivan Das Sheth v. State of Maharashtra (1962)

The Supreme Court interpreted the broad statutory definition of drugs under the Drugs and Cosmetics Act. Its reasoning is directly relevant to understanding the legal classification of substances used therapeutically.

6. Ishwar Singh Bindra v. State of Uttar Pradesh (1968)

The Supreme Court examined the interpretation of medicines and substances under the Drugs and Cosmetics Act. This decision is relevant to the statutory classification of therapeutic cellular materials.

7. State of Madhya Pradesh v. G.S. Dall and Flour Mills (1992)

The Supreme Court explained that executive instructions may supplement statutory rules but cannot override them. This is important when administrative orders modify committee approval arrangements.

6. COMPLIANCE AND PUBLIC SAFETY REQUIREMENTS

Obtain appropriate institutional ethical approval before conducting human research.

Ensure required CDSCO permissions before commencing regulated clinical trials.

Maintain qualified and independent scientific reviewers.

Obtain voluntary and adequately informed participant consent.

Maintain appropriate manufacturing and quality-control standards.

Establish adverse-event reporting and long-term safety monitoring.

Protect confidential patient and genetic information.

Prevent commercial promotion of unproven regenerative treatments.

Maintain auditable approval records and institutional accountability.

7. CONCLUSION

Regenerative medicine committee approvals are essential for ensuring that innovative cellular and tissue-based treatments develop within a scientifically reliable and ethically responsible regulatory environment. India's regulatory framework combines the Drugs and Cosmetics Act, 1940, NDCT Rules, 2019, ICMR guidelines, and institutional ethical oversight. The Supreme Court's decision in Yash Charitable Trust v. Union of India (2026) provides particularly important guidance on the legal requirements governing experimental stem cell treatments. Effective implementation requires independent committee review, appropriate CDSCO authorisation, informed consent, continuous monitoring, and clear institutional accountability. These safeguards ensure that scientific innovation does not compromise patient rights or public safety.